Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of α4 integrin

Abstract

Purpose: To determine the efficacy of a small molecule inhibitor of α₄ integrin (CT301) at reversing the clinical, pathological and MR- detectable deficits associated with the acute phase of experimental allergic encephalomyelitis (EAE). Materials and methods: EAE was induced in 36 female Hartley guinea pigs, and the treatment period was from day 11 to day 17 post-immunization. Animals received either saline (n=12), anti-α₄ integrin antibody (AN100226m; n=12) or CT301 (n=12). T2-weighted fast spin echo and T1-weighted pre- and post-contrast scans were performed at the beginning (day 11) and end (day 18) of the treatment period, and scored for cerebral inflammation and gadolinium enhancement. T1-weighted images were further analyzed to quantify this enhancement as a measure of blood-brain barrier integrity. Dissected CNS was evaluated for inflammation and demyelination. Results: CT301 successfully reversed two clinical indicators of disease over the course of the treatment period. These animals showed decreased T2-weighted abnormalities, as well as a reduction in gadolinium leakage on T1-weighted images. Meningeal and perivascular inflammation was decreased by anti-α₄ integrin treatments. Conclusion: CT301 effectively reverses the clinical, pathological and MR-detectable deficits of acute EAE, and may therefore be a promising therapeutic agent in multiple sclerosis (MS).

Keywords

α4 integrin experimental allergic encephalomyelitis magnetic resonance imaging multiple sclerosis small molecule therapeutic

Get full access to this article

View all access options for this article.

References

Filippi M , Grossman RI. MRI techniques to monitor MS evolution: the present and the future . Neurology 2002; 58: 1147-1153 .

Filippi M , Falini A , Arnold DL , Fazekas F , Gonen O , Simon JH et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group . J Magn Reson Imaging 2005; 21: 669-675 .

Miller DH , Filippi M , Fazekas F , Frederiksen JL , Matthews PM , Montalban X et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis . Ann Neurol 2004; 56: 273-278 .

O’Riordan JI , Thompson AJ , Kingsley DP , MacManus DG , Kendall BE , Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up . Brain 1998; 121: 495-503 .

Lassmann H , Wekerle H. Experimental models of multiple sclerosis. In Compston A , Ebers G , Lassmann H , McDonald I , Matthews B , Wekerle H eds. McAlpine’s multiple sclerosis. London: Churchill Livingstone , 1998: 409-433.

Hawkins CP , MacKenzie F , Tofts P , du Boulay EP , McDonald WI. Patterns of blood-brain barrier breakdown in inflamma-tory demyelination . Brain 1991; 114: 801-810 .

Namer IJ , Steibel J , Poulet P , Armspach JP , Mohr M , Mauss Y et al. Blood-brain barrier breakdown in MBP-specific T cell induced experimental allergic encephalomyelitis. A quantitative in vivo MRI study . Brain 1993; 116: 147-159 .

Seeldrayers PA , Syha J , Morrissey SP , Stodal H , Vass K , Jung S et al. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental auto-immune encephalomyelitis . J Neuroimmunol 1993; 46: 199-206 .

Karlik SJ , Grant EA , Lee D , Noseworthy JH. Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig . Magn Reson Med 1993; 30: 326-331 .

10.

Namer IJ , Steibel J , Piddlesden SJ , Mohr M , Poulet P , Chambron J. Magnetic resonance imaging of an antibody-mediated demyelinating experimental allergic encephalomyelitis . J Neuroimmunol 1994; 54: 41-50 .

11.

Morrissey SP , Stodal H , Zettl U , Simonis C , Jung S , Kiefer R et al. in vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema . Brain 1996; 119: 239-248 .

12.

Karlik SJ , Munoz D , St Louis J , Strejan G. Correlation between MRI and clinico-pathological manifestations in Lewis rats protected from experimental allergic encephalomyelitis by acylated synthetic peptide of myelin basic protein . Magn Reson Imaging 1999; 17: 731-737 .

13.

Juhler M , Barry DI , Offner H , Konat G , Klinken L , Paulson OB. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat . Brain Res 1984; 302: 347-355 .

14.

Hawkins CP , Munro PM , MacKenzie F , Kesselring J , Tofts PS , du Boulay EP et al. Duration and selectivity of blood-brain barrier breakdown in chronic-relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers . Brain 1990; 113: 356-378 .

15.

Grossman RI , Lisak RP , Macchi PJ , Joseph PM. MR of acute experimental allergic encephalomyelitis . AJNR Am J Neuroradiol 1987; 8: 1045-1048 .

16.

t’Hart BA , Bauer J , Muller HJ , Melchers B , Nicolay K , Brok H et al. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus) . Am J Pathol 1998; 153: 649-663 .

17.

Kuharik MA , Edwards MK , Farlow MR , Becker GJ , Azzarelli B , Klatte EC et al. Gd-enhanced MR imaging of acute and chronic experimental demyelinating lesions . AJNR Am J Neuroradiol 1988; 9: 643-648 .

18.

Yednock TA , Cannon C , Fritz LC , Sanchez-Madrid F , Steinman L , Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin . Nature 1992; 356: 63-66 .

19.

Baron JL , Madri JA , Ruddle NH , Hashim G , Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 cells is required for their entry into brain parenchyma . J Exp Med 1993; 177: 57-68 .

20.

Soilu-Hanninen M , Roytta M , Salmi A , Salonen R. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis . J Neuroimmunol 1997; 72: 95-105 .

21.

Brocke S , Piercy C , Steinman L , Weissman IL , Veromaa T. Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment . PNAS 1999; 96: 6896-6901 .

22.

Kent SJ , Karlik SJ , Rice GP , Horner HC. A monoclonal antibody to α4 integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig . J Magn Reson Imaging 1995; 5: 535-540 .

23.

Kent SJ , Karlik SJ , Cannon C , Hines DK , Yednock TA , Fritz LC et al. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis . J Neuroimmunol 1995; 58: 1-10 .

24.

Keszthelyi E , Karlik S , Hyduk S , Rice GP , Gordon G , Yednock T et al. Evidence for a prolonged role of α4 integrin throughout active experimental allergic encephalomyelitis . Neurology 1996; 47: 1053-1059 .

25.

Leger OJ , Yednock TA , Tanner L , Horner HC , Hines DK , Keen S et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis . Hum Antibodies 1997; 8: 3-16 .

26.

Tubridy N , Behan PO , Capildeo R , Chaudhuri A , Forbes R , Hawkins CP et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group . Neurology 1999; 53: 466-472 .

27.

Miller DH , Khan OA , Sheremata WA , Blumhardt LD , Rice GP , Libonati MA et al. A controlled trial of Natalizumab for relapsing multiple sclerosis . N Engl J Med 2003; 348: 15-23 .

28.

Jackson DY. Alpha 4 integrin antagonists . Curr Pharm Des 2002; 8: 1229-1253 .

29.

Kuchroo VK , Martin CA , Greer JM , Ju ST , Sobel RA , Dorf ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis . J Immunol 1993; 151: 4371-4382 .

30.

Engelhardt B , Laschinger M , Schulz M , Samulowitz U , Vestweber D , Hoch G. The development of experimental autoimmune encephalomyelitis in the mouse requires α4-integrin but not α4β7-integrin . J Clin Invest 1998; 102: 2096-2105 .

31.

van der Laan LJ , van der Goes A , Wauben MH , Ruuls SR , Dopp EA , De Groot CJ et al. Beneficial effect of modified peptide inhibitor of α4 integrins on experimental allergic encephalomyelitis in Lewis rats . J Neurosci Res 2002; 67: 191-199 .

32.

Piraino PS , Yednock TA , Freedman SB , Messersmith EK , Pleiss MA , Vandevert C et al. Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of α4 integrin . J Neuroimmunol 2002; 131: 147-159 .

33.

Bastianello S , Pozzilli C , Bernardi S , Bozzao L , Fantozzi LM , Buttinelli C et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis . Neurology 1990; 40: 591-595 .

34.

Kermode AG , Thompson AJ , Tofts P , MacManus DG , Kendall BE , Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications . Brain 1990; 113: 1477-1489 .